References
- Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459–2465
- Gokulgandhi MR, Vadlapudi AD, Mitra AK. Ocular toxicity from systemically administered xenobiotics. Expert Opin Drug Metab Toxicol 2012;8:1277–1291
- Gyatsho J, Kaushik S, Gupta A, et al. Retinal nerve fiber layer thickness in normal, ocular hypertensive, and glaucomatous Indian eyes: an optical coherence tomography study. J Glaucoma 2008;17:122–127
- Anderson RS, O'Brien C. Psychophysical evidence for a selective loss of M ganglion cells in glaucoma. Vision Res 1997;37:1079–1083
- Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3–10
- Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006;51:19–40
- Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982;39:719–720
- Urba S, Forastiere AA. Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer. Cancer 1988;62:2094–2097
- Shimamura Y, Chikama M, Tanimoto T, et al. Optic nerve degeneration caused by supraophthalmic carotid artery infusion with cisplatin and ACNU. Case report. J Neurosurg 1990;72:285–288
- Caraceni A, Martini C, Spatti G, et al. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand 1997;96:260–261
- Pinilla I, Garcia-Martin E, Idoipe M, et al. Comparison of retinal nerve fiber layer thickness measurements in healthy subjects using fourier and time domain optical coherence tomography. J Ophthalmol 2012;2012:107053
- Lee JY, Hwang YH, Lee SM, Kim YY. Age and retinal nerve fiber layer thickness measured by spectral domain optical coherence tomography. Korean J Ophthalmol 2012;26:163–168
- Bendschneider D, Tornow RP, Horn FK, et al. Retinal nerve fiber layer thickness in normals measured by spectral domain OCT. J Glaucoma 2010;19:475–482
- Riordan-Eva P. Clinical assessment of optic nerve disorders. Eye (Lond) 2004;18:1161–1168
- Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 1989;107:453–464
- Clark AW, Parhad IM, Griffin JW, Price DL. Neurotoxicity of cisplatinurn: pathology of the central and peripheral nervous systems (Abstr). Neurology 1980;30:429
- Maiese K, Walker RW, Gargan R, Victor JD. Intra-arterial cisplatin-associated optic and otic toxicity. Arch Neurol 1992;49:83–86
- Damascelli B, Cantù G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 2001;92:2592–2602
- Capri G, Munzone E, Tarenzi E, et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994;86:1099–1101
- Scaioli V, Caraceni A, Martini C, et al. Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case. J Neurooncol 1995;25:221–225
- Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol 1993;116:508–509